Boston Partners Has $625.50 Million Holdings in McKesson Co. (NYSE:MCK)

Boston Partners lifted its stake in McKesson Co. (NYSE:MCK) by 24.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,096,301 shares of the company’s stock after acquiring an additional 216,432 shares during the period. McKesson accounts for about 0.8% of Boston Partners’ investment portfolio, making the stock its 27th largest position. Boston Partners owned approximately 0.86% of McKesson worth $625,501,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in MCK. Synergy Asset Management LLC acquired a new position in shares of McKesson in the fourth quarter valued at $32,000. MidAtlantic Capital Management Inc. bought a new stake in shares of McKesson during the third quarter worth $29,000. Crews Bank & Trust bought a new stake in shares of McKesson during the fourth quarter worth $33,000. Atala Financial Inc bought a new stake in shares of McKesson during the fourth quarter worth $34,000. Finally, RPg Family Wealth Advisory LLC bought a new position in McKesson in the third quarter valued at about $31,000. 85.07% of the stock is owned by institutional investors.

Insider Activity at McKesson

In other McKesson news, CEO Brian S. Tyler sold 8,961 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $600.66, for a total transaction of $5,382,514.26. Following the sale, the chief executive officer now directly owns 69,625 shares in the company, valued at $41,820,952.50. This represents a 11.40 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Leann B. Smith sold 188 shares of the stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $609.59, for a total transaction of $114,602.92. Following the completion of the sale, the executive vice president now directly owns 1,051 shares in the company, valued at approximately $640,679.09. This represents a 15.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,689 shares of company stock valued at $11,187,351. Corporate insiders own 0.11% of the company’s stock.

McKesson Stock Performance

Shares of McKesson stock opened at $655.32 on Tuesday. The company has a fifty day moving average of $610.04 and a 200 day moving average of $571.65. McKesson Co. has a fifty-two week low of $464.42 and a fifty-two week high of $663.62. The company has a market capitalization of $82.13 billion, a P/E ratio of 30.01, a P/E/G ratio of 1.29 and a beta of 0.52.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $8.03 earnings per share for the quarter, missing the consensus estimate of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. Analysts forecast that McKesson Co. will post 32.77 EPS for the current year.

McKesson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Monday, March 3rd will be paid a dividend of $0.71 per share. The ex-dividend date of this dividend is Monday, March 3rd. This represents a $2.84 dividend on an annualized basis and a dividend yield of 0.43%. McKesson’s dividend payout ratio is currently 13.00%.

Analyst Ratings Changes

Several research firms have weighed in on MCK. Bank of America dropped their price target on McKesson from $680.00 to $650.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. StockNews.com downgraded McKesson from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th. Wells Fargo & Company lifted their price target on McKesson from $641.00 to $691.00 and gave the stock an “equal weight” rating in a report on Friday. Citigroup dropped their price objective on McKesson from $713.00 to $677.00 and set a “buy” rating for the company in a report on Friday, January 10th. Finally, Evercore ISI boosted their price objective on McKesson from $650.00 to $675.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $649.36.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.